Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Carvedilol Phosphate modified release formulation
Carvedilol modified release formulation · 1 trial · 1 indication
Blood draw for triglyceride levels. Full beta quantification test performed which uses ultracentrifugation to partially separate lipoprotein classes and is the basis for the reference methods. Change = Month 6 value minus Baseline value.
Blood draw for HDL-C levels. Full beta Quant test performed with HDL subclasses. Change = Month 6 value minus Baseline value.
| Arm | Type | Description |
|---|---|---|
| Carvedilol Phosphate modified release formulation | EXPERIMENTAL | - |
| metoprolol succinate | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Carvedilol Phosphate modified release formulation | DRUG | - |
| metoprolol succinate | DRUG | - |
Inclusion Criteria: * Documented history of hypertension * Triglycerides of 120-400 mg/mL * LDLc levels not requiring lipid lowering medication. Exclusion Criteria: * Has known contraindication to alpha- or beta-blocker therapy. * Has taken any non-ocular beta-blockers within three months before ...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Carvedilol modified release formulation is an investigational small molecule developed by GSK plc for hypertension. It is a once-daily extended-release version of carvedilol, also known as carvedilol phosphate modified release. It has completed Phase 3 clinical testing in adults with hypertension, including patients with normal or mildly elevated lipid levels.
Carvedilol modified release formulation is being developed for the treatment of hypertension, or high blood pressure. Its Phase 3 trial enrolled adults 18 years and older with hypertension, including patients who were normolipidemic or mildly dyslipidemic. The program is focused on cardiovascular medicine.
Carvedilol modified release formulation targets the alpha-1 adrenergic receptors ADRA1A, ADRA1B, and ADRA1D, and the beta-adrenergic receptors ADRB1, ADRB2, and ADRB3. It acts as an antagonist at these receptors, which is the mechanism associated with its blood pressure lowering activity in hypertension.
GSK plc, which trades under the ticker GSK, is the developer of carvedilol modified release formulation. The company sponsored the Phase 3 trial evaluating the asset in hypertension. GSK is the company name associated with this modified release carvedilol phosphate program.
Carvedilol modified release formulation has completed Phase 3 clinical development. It is an investigational product and is not described as FDA approved. The single Phase 3 trial, NCT00273052, is listed as completed, and no trials for this formulation are currently active.
Carvedilol modified release formulation was studied in the Phase 3 trial NCT00273052, titled COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension. The trial enrolled 514 participants across the United States, Canada, and Puerto Rico, was randomized, double blind, and active controlled, and is now completed.
Yes. Carvedilol modified release formulation is also known as carvedilol phosphate modified release formulation. Both names refer to the same GSK plc product candidate, a small molecule in Phase 3 development for hypertension. Searches using either name point to the same asset and the same clinical program.